249 related articles for article (PubMed ID: 34408079)
21. A critical role for Pin2/TRF1 in ATM-dependent regulation. Inhibition of Pin2/TRF1 function complements telomere shortening, radiosensitivity, and the G(2)/M checkpoint defect of ataxia-telangiectasia cells.
Kishi S; Lu KP
J Biol Chem; 2002 Mar; 277(9):7420-9. PubMed ID: 11744712
[TBL] [Abstract][Full Text] [Related]
22. Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition.
Deeg KI; Chung I; Bauer C; Rippe K
Front Oncol; 2016; 6():186. PubMed ID: 27602331
[TBL] [Abstract][Full Text] [Related]
23. Influence of ATM function on interactions between telomeres and nuclear matrix.
Pandita TK; Dhar S
Radiat Res; 2000 Aug; 154(2):133-9. PubMed ID: 10931683
[TBL] [Abstract][Full Text] [Related]
24. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
25. The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).
Pike KG; Barlaam B; Cadogan E; Campbell A; Chen Y; Colclough N; Davies NL; de-Almeida C; Degorce SL; Didelot M; Dishington A; Ducray R; Durant ST; Hassall LA; Holmes J; Hughes GD; MacFaul PA; Mulholland KR; McGuire TM; Ouvry G; Pass M; Robb G; Stratton N; Wang Z; Wilson J; Zhai B; Zhao K; Al-Huniti N
J Med Chem; 2018 May; 61(9):3823-3841. PubMed ID: 29683659
[TBL] [Abstract][Full Text] [Related]
26. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
27. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
28. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
29. ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction.
Reddy V; Wu M; Ciavattone N; McKenty N; Menon M; Barrack ER; Reddy GP; Kim SH
J Biol Chem; 2015 Oct; 290(42):25522-33. PubMed ID: 26336104
[TBL] [Abstract][Full Text] [Related]
30. Alternative Lengthening of Telomeres in Pediatric High-Grade Glioma and Therapeutic Implications.
Umaru B; Sengupta S; Senthil Kumar S; Drissi R
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370681
[TBL] [Abstract][Full Text] [Related]
31. Extra-chromosomal telomeric DNA in cells from Atm(-/-) mice and patients with ataxia-telangiectasia.
Hande MP; Balajee AS; Tchirkov A; Wynshaw-Boris A; Lansdorp PM
Hum Mol Genet; 2001 Mar; 10(5):519-28. PubMed ID: 11181576
[TBL] [Abstract][Full Text] [Related]
32. METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma.
Vaid R; Thombare K; Mendez A; Burgos-Panadero R; Djos A; Jachimowicz D; Lundberg KI; Bartenhagen C; Kumar N; Tümmler C; Sihlbom C; Fransson S; Johnsen JI; Kogner P; Martinsson T; Fischer M; Mondal T
Nucleic Acids Res; 2024 Mar; 52(5):2648-2671. PubMed ID: 38180812
[TBL] [Abstract][Full Text] [Related]
33. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; Suvà ML; Benes CH; Haber DA; Boussin FD; Zou L
Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
35. ATR cooperates with CTC1 and STN1 to maintain telomeres and genome integrity in Arabidopsis.
Boltz KA; Leehy K; Song X; Nelson AD; Shippen DE
Mol Biol Cell; 2012 Apr; 23(8):1558-68. PubMed ID: 22357613
[TBL] [Abstract][Full Text] [Related]
36. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
37. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1.
Denchi EL; de Lange T
Nature; 2007 Aug; 448(7157):1068-71. PubMed ID: 17687332
[TBL] [Abstract][Full Text] [Related]
38. Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease.
Zhang JQJ; Saravanabavan S; Rangan GK
Cells; 2021 Mar; 10(3):. PubMed ID: 33802342
[TBL] [Abstract][Full Text] [Related]
39. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
Claude E; Decottignies A
Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
[TBL] [Abstract][Full Text] [Related]
40. Methylation of
Li H; Yang W; Zhang M; He T; Zhou F; G Herman J; Hu L; Guo M
Epigenomics; 2021 Sep; 13(17):1403-1419. PubMed ID: 34558311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
